Overcoming time pressure and the global shortage of test kits and reagents, the 8-member Microbiology team from Gleneagles Hospital Hong Kong’s Clinical Laboratory has made in-house COVID-19 testing a reality, about two months after Hong Kong confirmed its first COVID-19 case.
Today, Gleneagles Hospital Hong Kong is capable of testing up to 150 COVID-19 samples daily in its laboratory. It uses two test platforms (POCT or point of care testing and PCR or polymerase chain reaction testing), to provide quality and efficient service to meet our patients’ needs.
Between end of March and end of May, the hospital tested more than 200 cases, while supporting the Hong Kong Government Department of Health’s Community Deep Throat Saliva Surveillance Programme with about 300 cases.
The team is ramping up the laboratory’s testing capacity to meet the anticipated surge in testing demand as the government prepares to open up its borders to businesses travellers with negative COVID-19 nucleic acid testing result certification.
By making COVID-19 testing available to our patients and the medical needs of our clinicians, Gleneagles Hospital Hong Kong is helping to stem the spread of the virus in the community. It is also keeping our hospital safe for our inpatients and frontline staff, ensuring that it continues to provide uninterrupted healthcare services during the COVID-19 pandemic.
Related Stories
2026 IHH Global Town Hall: Building a Future-ready Workforce
'Building a Future-ready Workforce' took centre stage at IHH Healthcare's 2026 Global Town Hall on 9 February, bringing colleagues together across 10 countries in a truly hybrid experience that underscored the group's commitment to future-proof healthcare.
IHH Malaysia Partners Libyan Government for Medical Referrals
IHH Healthcare Malaysia signed a Memorandum of Understanding (MOU) with The Government of Libya on 9 February, establishing a structured medical referral pathway for Libyan civil servants requiring specialist treatment at 18 hospitals across IHH’s Malaysian network.
Agilus Diagnostics Expands Access to Next-Generation Precision Genomics
Agilus Diagnostics, a subsidiary of Fortis Healthcare, has installed the Illumina NovaSeq X sequencing platform at its Mumbai reference laboratory, marking a major step forward for precision genomics in India.
Parkway Shanghai Opens International Centre for Hepatobiliary and Pancreatic Diseases
Mount Elizabeth Hospitals Celebrate 97 Wins at Singapore Health Quality Service Awards 2026
